Genentech

Genentech, Inc. is a pharmaceutical company and one of the world's most financially successful and biotechnology corporations. Genentech has three drugs that are billion-dollar sellers: Rituxan, for non-Hodgkin's lymphoma; Avastin, for colorectal, non-small cell lung cancers, and treats macular degeneration; and Herceptin for breast cancer. It also manufactures the lung cancer drug Tarceva. Major customers for its drugs are AmerisourceBergen, Cardinal Health, and McKesson. The Swiss drug company Roche, which previously owned a majority of stock in the San Francisco based firm, took full ownership in 2009. According to its website, the company is "considered the founder of the biotechnology industry."

In the fiscal year ending in December of 2008, Genentech had sales of 13.4 billion dollars and had 11,174 employees.

Animal testing
Genentech does animal testing.

Facility information, progress reports & USDA-APHIS reports
For links to copies of a facility's U.S. Department of Agriculture (USDA)-Animal Plant Health Inspection (APHIS) reports, other information and links, see also Stop Animal Experimentation NOW!: Facility Reports and Information. This site contains listings for all 50 states, links to biomedical research facilities in that state and PDF copies of government documents where facilities must report their animal usage. (Search: Genentech, Inc., San Francisco, California.)

USDA AWA reports
As of May 26, 2009, the USDA began posting all inspection reports for animal breeders, dealers, exhibitors, handlers, research facilities and animal carriers by state. See also USDA Animal Welfare Inspection Reports.

Toxic drug trials on foster children
See also foster child drug trials.

Selected staff & board

 * Arthur Levinson - Chairman
 * Ian Clark - CEO
 * Steve Krognes - CFO
 * Laura A. Leber
 * Amo Houghton

Former staff

 * J. Richard Munro - CEO
 * William D. Young - COO

Board

 * Herbert W. Boyer, PhD, Vice-Chairman of the Board - Allergan, Inc.
 * William M. Burns
 * Erich Hunziker
 * Jonathan K.C. Knowles, PhD
 * Arthur D. Levinson, PhD - Board - Apple Computer, Inc.
 * Debra L. Reed - Board - Halliburton Company
 * Charles A. Sanders, MD

Executive compensation (2007)

 * Arthur D. Levinson, Chairman, CEO - $17,124,025 (also exercised $66,268,100 in options)
 * Susan D. Desmond-Hellmann, Divisional President - $7,820,142 (also exercised $33,465,041 in options)
 * David A. Ebersman - CEO - $4,030,747
 * Stephen G. Juelsgaard - Executive VP - $4,896,340 (also exercised $24,980,534 in options)
 * Richard H. Scheller, Divisional Executive VP - $4,992,779 (also exercised $10,880,395 in options)

Political Contributions
Genentech gave almost $400,000 to candidates in the 2008 election cycle through its political action committee (PAC).

This is almost twice as much as in 2006, when it donated $201,500 to federal candidates. - 38% to Democrats and 57% to Republicans.

Lobbying
According to Lisa Graves of the Center for Media and Democracy, a search of the 2009 Lobby Disclosure Act database for Genentech, revealed that the company spent over $3.7 million lobbying Congress on health care issues in the first three quarters on the year. The company spent over $2.1 million dollars on in-house lobbyists with the remainder going to outside firms such as the American Continental Group.

Genetech's lobbying made the news after its talking points showed up in the statements submitted by several members of Congress to the Congressional Record (the official journal of congressional proceedings), during the 2009 health care reform debate.

Contact
Genentech, Inc. 1 DNA Way South San Francisco, CA 94080

Phone: 650-225-1000

Fax: 650-225-6000

Web address: http://www.gene.com

Sourcewatch articles

 * AIDS industry
 * Animal testing
 * Biotechnology
 * Foster child drug trials
 * HIV/AIDS
 * Pharmaceutical industry
 * Roche
 * Stephen Evans-Freke - former lead investment banker
 * War on Cancer